Arusha Ayub | Medicine | Best Researcher Award

Published on by Academic Excellence

Ms. Arusha Ayub | Medicine | Best Researcher Award

University of Georgia | Georgia

Arusha Ayub is a dedicated final-year medical student at the University of Georgia, pursuing a Doctor of Medicine (MD) degree at the College of Health Sciences. Her academic journey began at the International Indian Embassy School in Riyadh, Saudi Arabia, where she completed both her secondary (2018) and senior secondary (2020) education under the CBSE board. Driven by a passion for advancing clinical and translational medicine, she has actively engaged in impactful research at both the University of Georgia and King Saud University. At the Scientific Research Institute, University of Georgia, Arusha has contributed as a research assistant to the project “Epidemiological Assessment of Living Indicators According to Systems in the Last Days of Life of Patients in the Terminal Phase of Cancer.” Her work focuses on assessing nutrition and gastrointestinal function in terminal cancer patients using a variety of standardized clinical assessment tools, thereby enhancing understanding of end-of-life care and patient quality of life. In addition, Arusha serves as a research intern under the mentorship of Dr. Sultan Meo at King Saud University, Riyadh. Her role involves participation in clinical studies emphasizing real-world data, study design, data collection, analysis, and manuscript development. Through collaboration with multidisciplinary teams, she has demonstrated excellence in research integrity, clinical evaluation, and scientific communication. Arusha’s academic rigor and research engagement reflect her commitment to integrating evidence-based medicine with compassionate healthcare practice, positioning her as a promising future physician and medical researcher.

Profile:  Google Scholar

Featured Publication

1. Samad, M. A., Ahmad, I., Hasan, A., Alhashmi, M. H., Ayub, A., Al‐Abbasi, F. A., et al. (2025). STAT3 signaling pathway in health and disease. MedComm, 6(4), e70152.

2. Ayub, A., Sultana, N., Faruk, M. I., Rahman, M. M., & Mamun, A. N. M. (2009). Control of rhizome rot disease of ginger (Zingiber officinale Rose) by chemicals, soil amendments, and soil antagonists. The Agriculturists, 12, 57–61.

3. Sultana, N., Ayub, A., & Islam, M. (2008). Yield loss assessment of onion bulb due to purple blotch disease. Annual Research Report, Plant Pathology Division, Bangladesh Agricultural Research Institute (BARI), Joydevpur.

4. Deshmukh, M., Madankar, R., Chaudhary, R. G., Kalam, M. A., Ayub, A., Mondal, A., et al. (2025). Bioinspired sustainable development of Ag-CuO/MWCNT nanocomposites for antibacterial applications. Microbial Pathogenesis, 203, 107516.

5. Latif, M., Hashmi, J. A., Alayoubi, A. M., Ayub, A., & Basit, S. (2024). Identification of novel and recurrent variants in BTD, GBE1, AGL and ASL genes in families with metabolic disorders in Saudi Arabia. Journal of Clinical Medicine, 13(5), 1193.

Dorota Wasko-Czopnik | Medicine | Academic Excellence Award

Published on by Academic Excellence

Assoc. Prof. Dr. Dorota Wasko-Czopnik | Medicine | Academic Excellence Award

Assoc. Prof. Dr. Dorota Wasko-Czopnik | Medicine | Wrocław University of Science and Technology | Poland

Prof. Dorota Waśko-Czopnik, MD, PhD, is a distinguished physician, academic, and researcher specializing in internal medicine, gastroenterology, and nutrition. With over 26 years of service at the Clinic of Gastroenterology, Hepatology, and Internal Medicine at Wrocław Medical University, she has made remarkable contributions to clinical practice and medical education. She previously served as head of the Gastrointestinal Motility Laboratory, where she advanced diagnostic and therapeutic approaches for functional gastrointestinal disorders. Currently, she is affiliated with the Department of Gastroenterology and Hepatology and the Inflammatory Bowel Disease Treatment Unit at the Provincial Specialist Hospital in Wrocław, while also teaching at the Faculty of Medicine, Wrocław University of Science and Technology. Author of more than 180 publications, monographs, and books, Prof. Waśko-Czopnik bridges medicine with dietetics and nutrition, offering an integrative perspective on patient care. A respected mentor, she supervises theses and doctoral dissertations, inspiring the next generation of medical professionals.

Author Profile

Orcid

Education

Prof. Dorota Waśko-Czopnik’s educational path reflects excellence in both medicine and nutrition. She graduated with a medical degree (MD) and further advanced her expertise by obtaining a PhD, focusing her research on gastroenterology and internal medicine. Her rigorous medical training culminated in earning a second-degree specialization in internal medicine, solidifying her clinical and academic foundation. She further enhanced her expertise by becoming a certified nutritional consultant, aligning her medical knowledge with a holistic understanding of dietetics and nutrition in patient care. Throughout her academic journey, she consistently demonstrated leadership in medical research and teaching, contributing extensively to the development of medical education. She has actively participated in postgraduate training programs, professional courses, and continuous medical education, ensuring she remains at the forefront of advancements in gastroenterology and hepatology. Her multidisciplinary educational background uniquely positions her to integrate internal medicine, gastroenterology, and nutritional sciences for innovative medical practices.

Experience

Prof. Dorota Waśko-Czopnik’s professional career spans nearly three decades of dedicated service in clinical medicine, research, and academia. For 26 years, she worked at the Clinic of Gastroenterology, Hepatology, and Internal Medicine at Wrocław Medical University, where she served as head of the Gastrointestinal Motility Laboratory and an esteemed lecturer. In her role, she combined clinical responsibilities with mentoring students and young researchers, shaping the academic and professional growth of numerous medical practitioners. Currently, she contributes her expertise at the Department of Gastroenterology and Hepatology and the Inflammatory Bowel Disease Treatment Unit of the Provincial Specialist Hospital in Wrocław, while also holding an academic position at the Faculty of Medicine of the Wrocław University of Science and Technology. Her experience includes supervising bachelor’s, master’s, and doctoral theses and evaluating advanced academic dissertations. A sought-after speaker, she has presented at national and international conferences, podcasts, and webinars.

Awards and Honors

Throughout her distinguished career, Prof. Dorota Waśko-Czopnik has received recognition for her contributions to medicine, research, and education. Her extensive publication record of over 180 scientific works, monographs, and books highlights her as a leading voice in gastroenterology, hepatology, and nutrition. She has been invited as a keynote lecturer at prestigious medical and dietetic conferences, underscoring her impact on both clinical and academic communities. Her leadership as head of the Gastrointestinal Motility Laboratory earned her respect within the medical community for advancing diagnostic practices. Prof. Waśko-Czopnik’s role as a mentor and thesis supervisor has also been honored, reflecting her commitment to developing future leaders in medicine. She has been recognized by national and European professional societies, including memberships in the Polish Society of Gastroenterology and the European Crohn’s and Colitis Organization. Her accolades represent not only personal achievements but also her significant contributions to advancing healthcare standards.

Research Focus

Prof. Dorota Waśko-Czopnik’s research is rooted in the intersection of gastroenterology, internal medicine, and nutrition, with a strong emphasis on functional gastrointestinal disorders. She has conducted pioneering work in gastrointestinal motility, contributing to the diagnosis and treatment of complex digestive diseases. Her studies extend into hepatology and inflammatory bowel diseases, where she integrates clinical practice with evidence-based dietary interventions. A certified nutritional consultant, she explores the relationship between dietetics and gastrointestinal health, offering patients innovative treatment strategies that combine medical therapy with lifestyle and nutritional modifications. She is also deeply engaged in the study of neurogastroenterology and microscopic colitis, contributing to both national and international collaborations. Her holistic approach to research highlights the importance of integrating nutrition science into gastroenterology to improve patient outcomes. Her ongoing projects and publications continue to bridge gaps between medicine, research, and patient education, positioning her as a leader in modern gastroenterology.

Publication Titles

  1. Gastrointestinal Motility: Clinical Insights and Applications

  2. Advances in Functional Gastrointestinal Disorder Management

  3. Nutrition and Gastroenterology: Bridging Medicine with Dietetics

  4. Hepatology Perspectives in Internal Medicine Practice

  5. Clinical Approaches to Inflammatory Bowel Disease Treatment

  6. Dietetics in Digestive Health and Patient Care

  7. Comprehensive Guide to Gastroenterology for Practitioners

  8. International Trends in Gastroenterological Research

  9. Academic Contributions in Gastrointestinal Disease Studies

  10. Medical Podcasts and Webinars on Nutrition and Health

Conclusion

Prof. Dorota Waśko-Czopnik stands as a highly accomplished physician, academic, and researcher whose career seamlessly integrates internal medicine, gastroenterology, and nutrition. Her impactful publications, leadership in medical education, and clinical expertise position her as an influential figure advancing modern healthcare. By combining scientific rigor with holistic patient-centered care, she continues to inspire both peers and future medical professionals, leaving a lasting legacy in the field of medicine.

Thomas Lehrnbecher | Medicine | Best Researcher Award

Published on by Academic Excellence

Prof. Dr. Thomas Lehrnbecher | Medicine | Best Researcher Award

Prof. Dr. Thomas Lehrnbecher | Medicine | Goethe Universität Frankfurt | Germany

Dr. Thomas Lehrnbecher is a distinguished pediatric oncologist and hematologist, serving as Head of the Division of Pediatric Hematology and Oncology at Johann Wolfgang Goethe University, Frankfurt. With decades of experience, his clinical and research expertise lies in infections in immunocompromised pediatric patients, supportive care, and innovative therapeutic strategies for childhood cancers. His career spans leading roles in Germany and international collaborations at the National Cancer Institute, USA, where he trained as a post-doctoral fellow. A prolific researcher, he has published extensively in high-impact journals, shaping global practices in infection management and antifungal prophylaxis in children with cancer. Dr. Lehrnbecher has also contributed significantly to medical societies, committees, and working groups, reflecting his leadership in advancing pediatric oncology. Recognized with prestigious awards, he continues to drive progress in medicine through innovative research, clinical care, and mentorship, making him an influential figure in pediatric hematology and oncology worldwide.

Author profile 

Orcid

Education

Dr. Lehrnbecher’s medical training reflects a strong foundation in pediatrics and subspecialization in oncology and infectious diseases. He earned his Board Exam in General Pediatrics in 1996, establishing his clinical foundation. His academic excellence and leadership were recognized in 2005, when he was awarded a Professorship at Johann Wolfgang Goethe University, Frankfurt, one of Germany’s leading medical institutions. That same year, he also earned a Diploma in Pediatric Infectious Diseases from the German Society for Pediatric Infectious Diseases, strengthening his expertise in managing complex infections. In 2007, he completed his Board Exam in Pediatric Hematology and Oncology, formally certifying his specialization in childhood cancers and blood disorders. Combined with his post-doctoral fellowship at the National Cancer Institute (NIH, USA), his education and training provided him with exceptional clinical and research competencies, which now serve as the foundation of his international reputation in pediatric oncology and infection medicine.

Experience

Dr. Lehrnbecher has cultivated an impressive career spanning over two decades in pediatric hematology and oncology. Since 2001, he has served as a Senior Consultant at Johann Wolfgang Goethe University, Frankfurt, providing expertise in pediatric cancer care and mentoring young clinicians. In 2018, he advanced to Head of the Division of Pediatric Hematology and Oncology, where he oversees patient care, clinical programs, and research initiatives. Earlier in his career, he worked as a Consultant at the Children’s Hospital, University of Würzburg (1999–2000), where he gained valuable clinical insights. A pivotal moment came during his post-doctoral fellowship at the National Cancer Institute, NIH, USA (1996–1999), under Dr. Stephen Chanock, where he developed a strong research focus on infections in immunocompromised children. His leadership in both clinical and research settings reflects his dedication to integrating science with practice, driving advancements in pediatric oncology, supportive care, and infection management worldwide.

Awards and Honors

Dr. Lehrnbecher’s contributions to pediatric oncology and infectious diseases have earned him numerous prestigious awards. In 2024, he received the Best Publication Award from the German Society of Mycology (DMykG), recognizing his impactful research. He previously won the Kind Philipp Award from the German Society of Pediatric Oncology and Hematology (GPOH) and the Poster Award from the International Society of Pediatric Oncology (SIOP). His groundbreaking work in mycology earned him the Outstanding Research in Mycology Award, while his contributions to histiocytic disorders were honored with the Nesbit Award from the Histiocyte Society. Earlier in his career, he was recognized with the Outstanding Research Award in Novel Therapeutic Strategies by the Children’s Cancer Foundation Mainz and the Educational Grant from the German Foundation of Cancer Aid. Collectively, these awards highlight his sustained excellence in clinical care, medical research, and innovation.

Research Focus

Dr. Lehrnbecher’s research is centered on improving the management of infections in immunocompromised pediatric patients, particularly those undergoing cancer treatment or hematopoietic stem cell transplantation. He has extensively studied antifungal prophylaxis, bacterial infections, and novel diagnostic markers for invasive fungal disease in children. His investigations aim to refine supportive care strategies, reduce infection-related mortality, and improve the quality of life for pediatric cancer patients. A particular focus of his research has been the efficacy of antifungal and antibiotic therapies, as well as the development of evidence-based guidelines for infection management. Beyond infectious diseases, his work also contributes to optimizing cancer treatment protocols, including long-term maintenance therapies for pediatric sarcomas. Through clinical trials, prospective studies, and international collaborations, Dr. Lehrnbecher has made significant advances in pediatric oncology. His contributions are widely recognized for bridging research and practice, helping set global standards for supportive care in children with cancer.

Publications

  • Assessing the Theoretical Efficacy of Combination Therapy Against Gram-Negative Infections in Neutropenic Pediatric Cancer Patients.

  • Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation.

  • Pediatric Patients with Stage IV Rhabdomyosarcoma Benefit from Long-Term Maintenance Therapy: CWS Trials Results.

  • Serum Beta-D-Glucan in the Diagnosis of Invasive Fungal Disease in Children: A Critical Analysis.

  • Cerebrospinal Fluid System Infection in Children with Cancer: A 14-Year Retrospective Analysis.

  • Infections during Non-Neutropenic Episodes in Pediatric Cancer Patients: A Prospective European Study.

Conclusion

Dr. Thomas Lehrnbecher is an internationally recognized leader in pediatric oncology and infectious diseases. His pioneering research, clinical leadership, and commitment to advancing supportive care in childhood cancer treatment have transformed patient outcomes worldwide. His achievements and continued impact make him a highly deserving candidate for the Medicine Award, symbolizing excellence in medical research and clinical innovation.

Do Young Kim | Medicine | Best Researcher Award

Published on by Academic Excellence

Prof. Do Young Kim | Medicine | Best Researcher Award

Prof. Do Young Kim, Yonsei University College of Medicine South Korea

Do Young Kim is a Professor of Internal Medicine at Yonsei University College of Medicine and a hepatologist at Severance Hospital in Seoul, Korea. Having been part of the faculty since 2007, Dr. Kim is widely recognized for his contributions to hepatology, particularly in hepatocellular carcinoma (HCC). He earned his medical degree from Yonsei University in 1996 and completed his training at Severance Hospital. Dr. Kim’s research experience includes a position as a research associate at Fred Hutchinson Cancer Research Center from 2011 to 2012, where he focused on proteomics and microRNA in HCC.

Professional Profile 

Scopus 

Orcid

Google Scholar

Summary of Suitability for the “Research for Best Researcher Award”

Professor Do Young Kim, a prominent figure in hepatology and internal medicine, has made significant contributions to the field of hepatocellular carcinoma (HCC) and hepatitis C research. As a professor at Yonsei University College of Medicine and a hepatologist at Severance Hospital, he has established himself as a leading expert in his field since 2007. His academic background, including his degree from Yonsei University and specialized training at Severance Hospital, laid a solid foundation for his remarkable career.

His research focus on proteomics and microRNA in HCC, particularly during his tenure at the Fred Hutchinson Cancer Research Center, has led to innovative insights into the mechanisms underlying liver cancer and hepatitis C. This focus has translated into a series of impactful publications, where he has served as the corresponding author in studies that explore new treatment paradigms and diagnostic advancements for HCC. His work on the efficacy and safety of various treatments, including sorafenib and lenvatinib, has become essential reading for clinicians and researchers alike.

🎓 Education 

Dr. Do Young Kim obtained his medical degree from Yonsei University in Seoul, Korea, in 1996. After completing his studies, he underwent medical training at Severance Hospital, where he continued his professional development until 2001. In 2011, Dr. Kim broadened his academic horizons by becoming a research associate at Fred Hutchinson Cancer Research Center, where he focused on proteomics and microRNA in hepatocellular carcinoma (HCC). This international research experience allowed him to deepen his expertise in the molecular aspects of liver cancer. Dr. Kim’s ongoing contributions to medical education and his research have been deeply influenced by his foundational education and global training experiences.

💼 Professional Experience 

Dr. Do Young Kim is currently serving as a Professor of Internal Medicine at Yonsei University College of Medicine and a hepatologist at Severance Hospital in Seoul, Korea. Since joining Severance Hospital in 2007, he has become an integral part of the team, specializing in hepatology and liver diseases. His research has advanced understanding in areas such as hepatocellular carcinoma (HCC) and hepatitis C. In 2011-2012, Dr. Kim expanded his professional expertise by working as a research associate at the Fred Hutchinson Cancer Research Center in Seattle, USA. There, he conducted cutting-edge research in proteomics and microRNA in relation to HCC, which added a new dimension to his medical and scientific career. His ongoing clinical and research contributions have made him a leader in the field of hepatology.

🏅 Awards and Recognition

Dr. Do Young Kim has received significant recognition in the field of hepatology, with several prestigious awards throughout his career. His research on hepatocellular carcinoma (HCC) and hepatitis C has earned him acknowledgment both nationally and internationally. He is particularly recognized for his contributions to clinical practices surrounding HCC and his extensive publication record in highly respected medical journals. His role as a corresponding author in key studies, such as those published in Hepatology and J Gastroenterol Hepatol, highlights his leadership in advancing knowledge about liver disease. Dr. Kim’s research and clinical expertise have earned him the trust and respect of colleagues in the medical community, solidifying his position as a leading expert in the field of internal medicine and hepatology.

🌍 Research Skills On Medicine

Dr. Do Young Kim’s research skills are highly regarded, particularly in the fields of hepatocellular carcinoma (HCC) and hepatitis C. He specializes in proteomics and microRNA, utilizing these molecular techniques to gain deeper insights into the pathophysiology of liver diseases. His time at the Fred Hutchinson Cancer Research Center honed his skills in advanced research methodologies, which he continues to apply in his work at Severance Hospital and Yonsei University College of Medicine. Dr. Kim’s research is both experimental and clinical, bridging the gap between laboratory findings and real-world medical applications. He is skilled in conducting large-scale studies, analyzing complex data, and collaborating with multidisciplinary teams to advance scientific understanding. His research has led to significant clinical improvements in the management of liver diseases, particularly in HCC treatment and early detection.

📖 Publication Top Notes

  • Letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
    • Authors: Chon, Y.E., Kim, D.Y., Chon, H.J., Kim, D.Y.
    • Citation: Clinical and Molecular Hepatology, 2025, 31(1), pp. e98–e100
  • The Possible Impact of Zinc-Enriched Multivitamins on Treatment-Naïve Recurrent Aphthous Stomatitis Patients
    • Authors: Seo, H.R., Chung, K.B., Kim, D.-Y.
    • Citation: Journal of Clinical Medicine, 2025, 14(1), 260
  • Survey on Alopecia Areata Patients’ Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study
    • Authors: Kim, J.E., Lee, S., Kang, H., Lee, Y.W., Kim, M.-B.
    • Citation: Annals of Dermatology, 2024, 36(6), pp. 376–383
  • Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study
    • Authors: Kim, K.-P., Kim, K.M., Ryoo, B.-Y., Kim, J.-A., Kim, K.-H.
    • Citation: Liver Cancer, 2024, 13(6), pp. 610–628
  • Detection of NUDT15 R139C Variants and Azathioprine Utilization in Patients with Dermatologic Conditions
    • Authors: Chung, K.B., Sung, H., Kim, D.-Y.
    • Citation: International Journal of Dermatology, 2024, 63(3), pp. e75–e77
  • Quantitative Analysis of Hair Luster in a Novel Ultraviolet-Irradiated Mouse Model
    • Authors: Chung, K.B., Lee, Y.I., Kim, Y.J., Kim, D.-Y., Lee, J.H.
    • Citation: International Journal of Molecular Sciences, 2024, 25(3), 1885
    • Citations: 1
  • Heterogeneity in Keloid Scars: Influence of Mechanical Stretching on Keloids Arising from Different Anatomical Sites
    • Authors: Lee, Y.I., Yang, Y., Ham, S., Kim, D.-Y., Lee, J.H.
    • Citation: Journal of Investigative Dermatology, 2024
  • The Efficacy of Treatment for Hepatocellular Carcinoma in Elderly Patients
    • Authors: Lee, H.A., Lee, S., Lee, H.L., Rhim, H., Kim, D.Y.
    • Citation: Journal of Liver Cancer, 2023, 23(2), pp. 362–376
    • Citations: 2
  • Predictive Biomarkers of Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Treatment
    • Authors: Chon, Y.E., Cheon, J., Kim, H., Chon, H.J., Kim, B.K.
    • Citation: Cancer Medicine, 2023, 12(3), pp. 2731–2738
    • Citations: 26
  • Activated TAZ Induces Liver Cancer in Collaboration with EGFR/HER2 Signaling Pathways
    • Authors: Moon, H., Park, H., Chae, M.J., Kim, D.Y., Ro, S.W.
    • Citation: BMC Cancer, 2022, 22(1), 423
    • Citations: 11